Davis P J, McGowan F X, Landsman I, Maloney K, Hoffmann P
Department of Anesthesiology, University of Pittsburgh School of Medicine, Pennsylvania, USA.
Anesthesiology. 1995 Nov;83(5):956-60. doi: 10.1097/00000542-199511000-00007.
Postoperative nausea and vomiting continue to be a significant problem for pediatric ambulatory surgery patients. Although ondansetron has been demonstrated to be effective in the prophylactic treatment of postoperative nausea and vomiting (surrogate end point) no one has demonstrated a benefit of antiemetic therapy on patient recovery, postanesthesia care unit length of stay, and hospital length of stay (nonsurrogate end points). In a double-blind manner, the effects of ondansetron, droperidol, and placebo on the incidence of emesis, postanesthesia care unit stay, and hospital discharge time were evaluated in children undergoing dental surgery.
The subjects were 102 children aged 2-8 years undergoing complete dental restoration. All patients received midazolam before undergoing inhalation induction of anesthesia with N2O/O2 and halothane. Anesthesia was maintained with N2O/O2 and alfentanil. Patients were then randomized to receive ondansetron (0.1 mg/kg), droperidol (75 micrograms/kg), or placebo (normal saline) in a double-blind fashion. At the conclusion of the anesthesia, a trained nurse observer assessed patient recovery and recorded the time patients met specified criteria for postanesthesia care unit and hospital discharge as well as episodes of emesis in the hospital and at home during the first 24 hr after surgery.
Ninety-five patients completed the study. The three antiemetic groups were similar with respect to age, weight, length of surgery, dose of alfentanil, and route of preanesthetic medication. The 24-hr incidence of emesis was significantly less with ondansetron (9%) than with placebo (35%) or droperidol (32%). Ondansetron-treated patients had significantly shorter hospital stays than droperidol-treated patients, but recovery parameters were similar between the ondansetron- and placebo-treated patients.
Ondansetron is an effective prophylactic antiemetic agent for children undergoing dental surgery. Compared with droperidol, ondansetron decreases the length of hospital stay, but compared to placebo, there were no differences in the patient recovery parameters.
术后恶心呕吐仍是小儿门诊手术患者面临的一个重要问题。尽管已证明昂丹司琼在预防术后恶心呕吐(替代终点)方面有效,但尚无研究表明止吐治疗对患者恢复、麻醉后监护病房住院时间和住院时间(非替代终点)有何益处。本研究以双盲方式,评估了昂丹司琼、氟哌利多和安慰剂对接受牙科手术儿童呕吐发生率、麻醉后监护病房住院时间和出院时间的影响。
研究对象为102例年龄在2至8岁接受全口牙齿修复的儿童。所有患者在接受N2O/O2和氟烷吸入诱导麻醉前均接受了咪达唑仑。麻醉维持采用N2O/O2和阿芬太尼。然后患者被随机双盲接受昂丹司琼(0.1mg/kg)、氟哌利多(75μg/kg)或安慰剂(生理盐水)。麻醉结束时,由一名经过培训的护士观察员评估患者的恢复情况,并记录患者达到麻醉后监护病房和出院的指定标准的时间,以及术后24小时内在医院和家中的呕吐发作情况。
95例患者完成了研究。三个止吐组在年龄、体重、手术时间、阿芬太尼剂量和麻醉前用药途径方面相似。昂丹司琼组的24小时呕吐发生率(9%)显著低于安慰剂组(35%)或氟哌利多组(32%)。接受昂丹司琼治疗的患者住院时间明显短于接受氟哌利多治疗的患者,但接受昂丹司琼和安慰剂治疗的患者恢复参数相似。
昂丹司琼是接受牙科手术儿童有效的预防性止吐药。与氟哌利多相比,昂丹司琼可缩短住院时间,但与安慰剂相比,患者恢复参数无差异。